{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:15Z","timestamp":1788243375213,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.yebeh.2019.106657","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T22:55:15Z","timestamp":1573512915000},"page":"106657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy"],"prefix":"10.1016","volume":"102","author":[{"given":"Elena","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Abraira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estevo","family":"Santamarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.106657_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0015","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14656566.2017.1328499","article-title":"Anticonvulsant drugs for generalized tonic\u2013clonic epilepsy","volume":"18","author":"Coppola","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2019.106657_bb0020","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/epi.13761","article-title":"Long-term outcome in adolescent-onset generalized genetic epilepsies","volume":"58","author":"Vorderw\u00fclbecke","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0025","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0030","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy","volume":"31","author":"Miskin","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2019.106657_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ebcr.2017.08.001","article-title":"Lacosamide for refractory generalized tonic\u2013clonic seizures of non-focal origin in clinical practice: a clinical and VEEG study","volume":"24","author":"Abarrategui","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2019.106657_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","article-title":"Lacosamide for uncontrolled primary generalized tonic\u2013clonic seizures: an open-label pilot study with 59-week extension","volume":"130","author":"Wechsler","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106657_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40120-016-0043-7","article-title":"Cognitive profile of zonisamide and valproic acid in the treatment of idiopathic generalized epilepsy: a comparative observational study","volume":"5","author":"Ramirez-Garc\u00eda","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2019.106657_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/epd.2009.0239","article-title":"Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy","volume":"11","author":"Marinas","year":"2009","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2019.106657_bb0055","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.clinph.2008.02.008","article-title":"Zonisamide decreases cortical excitability in patients with idiopathic generalized epilepsy","volume":"119","author":"Joo","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2019.106657_bb0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","article-title":"Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus","volume":"9","author":"Strzelczyk","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2019.106657_bb0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/epi.12973","article-title":"Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats","volume":"56","author":"Dupuis","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/epi.13638","article-title":"Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"58","author":"Wood","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"issue":"Suppl. 8","key":"10.1016\/j.yebeh.2019.106657_bb0080","article-title":"UCB 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo","volume":"44","author":"Matagne","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0085","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1212\/01.wnl.0000271385.85302.55","article-title":"Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model","volume":"69","author":"Kasteleijn-Nolst Trenite","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106657_bb0090","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0095","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106657_bb0105","first-page":"21","article-title":"A glossary of terms most commonly used by clinical electroencephalographers and proposal for the report form for the EEG findings","volume":"52","author":"Noachtar","year":"1999","journal-title":"Electroencephalogr Clin Neurophysyiol Suppl"},{"key":"10.1016\/j.yebeh.2019.106657_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNP.0b013e3182784729","article-title":"American Clinical Neurophysiology Society's standardized critical care EEG terminology: 2012 version","volume":"30","author":"Hirsch","year":"2013","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2019.106657_bb0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","article-title":"Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis","volume":"61","author":"Hirsch","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.106657_bb0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE\u2014a multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"134","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2019.106657_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.seizure.2016.11.008","article-title":"The adverse event profile of brivaracetam: a meta-analysis of randomized controlled trials","volume":"45","author":"Zhu","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.106657_bb0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/WNF.0000000000000258","article-title":"Anger assessment in patients treated with brivaracetam","volume":"41","author":"Ortega","year":"2018","journal-title":"Clin Neuropharmacol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930842X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930842X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:32:39Z","timestamp":1761503559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550501930842X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":26,"alternative-id":["S152550501930842X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106657","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106657"}}